Tirzepatide on NCBI and PubMed: reading the clinical evidence clearly

Step 1: understanding what the NCBI record for tirzepatide actually contains

NCBI's PubMed database is the standard index for peer-reviewed medical literature, and searching 'tirzepatide' there returns the full SURMOUNT programme — the series of phase 3 randomised controlled trials that Eli Lilly ran before seeking regulatory approval. SURMOUNT-1 is the landmark entry: 2,539 adults with obesity but without type 2 diabetes, 72 weeks, five treatment arms. The headline figures (roughly 20% average body-weight reduction at 10 mg and around 20–21% at 15 mg) come from that paper, published in the New England Journal of Medicine.

What the raw PubMed abstract does not spell out for a UK reader is how those figures translate into a licensed product and a prescribing framework. That step happened when the MHRA authorised Mounjaro for weight management and NICE completed its technology appraisal. Reading the NCBI record alongside NICE's appraisal of tirzepatide (TA1026) gives the fuller picture: the trial population, the approved population, the criteria, and what 'weight management' means in practice (reduced-calorie diet and increased physical activity alongside the injection).

The PubMed record also shows the SURMOUNT-2 paper, which covered adults with type 2 diabetes, and the SURMOUNT-5 head-to-head comparison with semaglutide 2.4 mg, both useful context, though neither changes UK licensing or eligibility criteria on its own.

Step 2: how the evidence shaped the licensed schedule and dosing logic

The SURMOUNT programme informed the licensed starting dose of 2.5 mg. That first pen exists to settle the digestive system rather than to drive weight loss, nausea is the most common early side effect, and the graduated titration (typically moving up in 4-week steps through 5, 7.5, 10 mg, which our tirzepatide 10 page covers in detail, 12.5 and 15 mg) mirrors the dose-escalation design used in the trials. Prescribers follow that logic when they decide whether a patient is ready to move up.

For a practical sense of what storing the medicine looks like: each Mounjaro KwikPen lives in the fridge door (2–8°C), and the SmPC sets a limited window for room-temperature use, the Patient Information Leaflet gives the exact timeframe, and that is always the source to check rather than any website. The NHS tirzepatide medicine guide summarises storage and common side effects in plain language.

Understanding the trial phases also helps set realistic expectations. The 20–21% figures are averages across a trial population; individual responses in clinical practice vary, and NICE's guidance notes that treatment should be reviewed if weight loss is under 5% after six months at the highest tolerated dose. That review is a clinical conversation, not an automatic stop.

Step 3: from published evidence to a UK prescription, the actual process

Because tirzepatide is a prescription-only medicine, the path from 'I've read the NCBI papers' to 'I have a pen in my fridge' runs through clinical assessment, not through a website basket. A GPhC-registered Independent Prescriber reviews the individual's medical history, current medicines, BMI, and weight-related conditions before any prescription is issued.

The licensed private eligibility criteria reflect the trial populations: adults aged 18 and over with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as hypertension, high cholesterol, prediabetes, type 2 diabetes, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. BMI alone is never the whole picture, the prescriber looks at the complete clinical context, including whether a higher maintenance dose such as tirzepatide 30 mg is a consideration worth exploring.

For people curious about how the evidence compares between tirzepatide and other options, the Mounjaro or tirzepatide page explains the naming, and the wider weight-loss treatments overview sets out what is licensed in the UK. On the cost side, the Mounjaro pricing page covers what private treatment typically involves, useful context before starting a consultation. The tirzepatide overview covers the mechanism in more depth, and if you want to understand how the letter-coded formulations differ, our tirzepatide l page goes into that specifically.

A question our prescribers hear regularly: 'Does reading the trial paper mean I qualify?' The research establishes that the medicine works at a population level. Whether it is right for a specific person is a separate, individual assessment. That is what clinical review is for.

If you'd like that assessment, check your eligibility with our prescribers, the consultation is free, and a real clinician reads your answers the same day.